Regencell Bioscience (RGC) has had the highest return since January 1, 2025 by a US stock with a market cap of $202+, returning 12,819.2%.
| ASSET | % RETURN |
|---|---|
Regencell Bioscience (RGC) | 12,819.16% |
QMMM Holdings Limited Ordinary Shares (QMMM) | 9,155.81% |
Abivax SA American Depositary Shares (ABVX) | 1,528.59% |
Diginex Limited Ordinary Shares (DGNX) | 1,240.85% |
FiEE (FIEE) | 1,202.75% |
Oncology Institute (TOI) | 1,132.03% |
Zepp Health (ZEPP) | 988.85% |
Abits (ABTS) | 791.85% |
Relmada Therapeutics (RLMD) | 740.4% |
Cidara Therapeutics (CDTX) | 711.88% |
Terns Pharmaceuticals (TERN) | 680.32% |
Celcuity LLC (CELC) | 672.92% |
DeFi Development (DFDV) | 671.29% |
Palvella Therapeutics (PVLA) | 666.41% |
Nanobiotix (NBTX) | 618.49% |
Newegg Commerce (NEGG) | 614.5% |
NovaBay Pharmaceuticals (NBY) | 594.87% |
Avino Silver & Gold Mines (ASM) | 568.13% |
AXT (AXTI) | 568.02% |
Galecto (GLTO) | 561.09% |
Rich Sparkle Holdings Limited Ordinary Shares (ANPA) | 543.61% |
Lizhi (SOGP) | 525.03% |
Americas Silver (USAS) | 510.53% |
Olema Pharmaceuticals (OLMA) | 505.24% |
Hycroft Mining (HYMC) | 478.32% |
